Grifols (CHIX:GRFE) Total Liabilities : €12,289 Mil (As of Sep. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Grifols Total Liabilities?

Grifols's Total Liabilities for the quarter that ended in Sep. 2024 was €12,289 Mil.

Grifols's quarterly Total Liabilities increased from Dec. 2023 (€13,468.57 Mil) to Jun. 2024 (€13,996.18 Mil) but then declined from Jun. 2024 (€13,996.18 Mil) to Sep. 2024 (€12,288.58 Mil).

Grifols's annual Total Liabilities increased from Dec. 2021 (€11,916.74 Mil) to Dec. 2022 (€13,076.43 Mil) and increased from Dec. 2022 (€13,076.43 Mil) to Dec. 2023 (€13,468.57 Mil).

Grifols Total Liabilities Historical Data

The historical data trend for Grifols's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Total Liabilities Chart

Grifols Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

8,696.84

8,554.72

11,916.74

13,076.43

13,468.57

Grifols Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23	Jun24	Sep24
Total Liabilities	Get a 7-Day Free Trial															13,209.18	13,495.81	13,468.57	13,996.18	12,288.58

Grifols Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Grifols's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2315.604	+	(9219.524	+	830.846
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	1002.436	+	100.159)
	=	13,469

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	21441.054	-	7972.485
	=	13,469

Grifols's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2355.575	+	(0	+	9933.009
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	12,289

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	20283.644	-	7995.06
	=	12,289

Grifols Total Liabilities Related Terms

Thank you for viewing the detailed overview of Grifols's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Grifols Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (CHIX:GRFe) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

GIKLY:USA GIFOF:USA GIFLF:USA GRFS:USA GRFPe:UK 0RDV:UK 0RDU:UK GRF.P:Spain GRF:Spain G0F0:Germany GRF:Austria

Address

Avinguda de la Generalitat, 152, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174

Website

https://www.grifols.com

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.

Grifols Headlines

No Headlines